Trial Roundup: PRTX-100 for Immune Thrombocytopenia, APR-246 for Myeloid Neoplasms, and more
ASH Clinical News' Associate Editors select clinical trials to keep an eye on in leukemia, bleeding disorders, and lymphoma & myeloma.David Steensma, MD
Dana-Farber Cancer Institute
A...
Vadastuximab Talirine in Higher-Risk MDS, Low-Dose Rituximab for Acquired TTP, and more
ASH Clinical News' Associate Editors select clinical trials to keep an eye on in leukemia, bleeding disorders, and lymphoma & myeloma.David Steensma, MD
Dana-Farber Cancer Institute
Study...
Evaluating Acalabrutinib for Hematologic Malignancies, Minimizing Menorrhagia in Women With Type 1 Von Willebrand...
LEUKEMIA
David Steensma, MD
Dana-Farber Cancer Institute
Phase 1 Trial to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of Splicing Modulator H3B-8800 for Subjects With Myelodysplastic Syndromes, Acute...
Introducing the Beat AML Master Trial, and more
The Beat AML Master Trial
Study Design: Observational, prospective cohort study
Study Start Date: November 2016
Estimated Study Completion Date: November 2023
Study Status:...
Clinical Trials for Rare Diseases
Below, we take a look at ongoing clinical trials for rare diseases. In addition to searching for new therapeutic targets and developing novel drugs...
Biomarker-Directed Trial for AML or MDS, Safety and Efficacy of BMN 270 for Hemophilia,...
LEUKEMIA
David Steensma, MD
Dana-Farber Cancer Institute
Controlled Study of Rigosertib Versus Physician’s Choice of Treatment in MDS Patients After Failure of an HMA (INSPIRE) (NCT02562443)
Study...
T Cell Therapy for Previously Treated Multiple Myeloma, Emicizumab in Hemophilia A Patients With...
LEUKEMIA
David Steensma, MD
Dana-Farber Cancer Institute
A Two-Arm Phase II Clinical Study of the Clinical Efficacy and Safety of Tosedostat in Patients With Myelodysplastic Syndromes (MDS)...
Lenalidomide Plus R-CHOP in DLBCL, New Gene Therapies for Hemophilia B , and more
LEUKEMIA
David Steensma, MD
Dana-Farber Cancer Institute
A Safety and Tolerability Study of Crenolanib in Combination With Chemotherapy in Newly Diagnosed Acute Myeloid Leukemia Patients With FLT3...
CAR T Cells in AML, Preventing VTE in Cancer Patients, and more
LEUKEMIA
David Steensma, MD
Dana-Farber Cancer Institute
Phase 1b Acute Myelogenous Leukemia (AML) Study with ABT-199 + Decitabine or Azacitidine (Chemo Combo) (NCT02203773)
Study Design: Phase Ib,...
4D Study, Rivaroxaban, and more
BLEEDING DISORDERS
Alice Ma, MD
University of North Carolina School of Medicine
This month’s benign hematology section focuses on the prevention and management of venous thromboembolism (VTE).
The...
Current Issue
November 2018, Volume 4, Issue 13
This issue features a look at the U.S. drug pricing system, attempts to solve physician burnout, and more.
